Morphological Characteristic of Melanoma B16 Progression in C57BL/6 Mice with High and Low Resistance to Hypoxia
暂无分享,去创建一个
O. Makarova | D. Khochanskiy | N. Zolotova | A. Kosyreva | E. A. Ponomarenko | I. Fridman | I. Tsvetkov | V. Mkhitarov | E. Postovalova
[1] E. Unger,et al. Overcoming tumor hypoxia as a barrier to radiotherapy, chemotherapy and immunotherapy in cancer treatment , 2018, International journal of nanomedicine.
[2] E. Swenson,et al. High Altitude and Cancer Mortality. , 2018, High altitude medicine & biology.
[3] Н. А. Лыжко. Молекулярно-генетические механизмы инициации, промоции и прогрессии опухолей , 2017 .
[4] E. Cicinelli,et al. Biological Pathways Involved in Tumor Angiogenesis and Bevacizumab Based Anti-Angiogenic Therapy with Special References to Ovarian Cancer , 2017, International journal of molecular sciences.
[5] U. Flögel,et al. Growth and metastasis of B16-F10 melanoma cells is not critically dependent on host CD73 expression in mice , 2014, BMC Cancer.
[6] D. Navajas,et al. Intermittent hypoxia increases melanoma metastasis to the lung in a mouse model of sleep apnea , 2013, Respiratory Physiology & Neurobiology.
[7] E. Gershtein,et al. Vascular Endothelial Growth Factor and Type 2 Receptor for This Factor in Vascular Malformations , 2011, Bulletin of Experimental Biology and Medicine.
[8] R. Ian Freshney,et al. Culture of Animal Cells: A Manual of Basic Technique and Specialized Applications , 2010 .
[9] G. Semenza. Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics , 2010, Oncogene.
[10] P. Vaupel,et al. Tumor hypoxia: causative factors, compensatory mechanisms, and cellular response. , 2004, The oncologist.
[11] G. Nicolson,et al. Organ selectivity for implantation survival and growth of B16 melanoma variant tumor lines. , 1976, Journal of the National Cancer Institute.
[12] I. Fidler,et al. Selection of successive tumour lines for metastasis. , 1973, Nature: New biology.